artificial intelligence Archives -

Sanofi has tapped into the artificial intelligence expertise of Chinese biotech Insilico Medicine with a six-compound drug discovery

Sanofi signs $1.2bn research alliance with AI specialist Insilico

https://pharmaphorum.com/news/sanofi-signs-1-2bn-research-alliance-with-ai-specialist-insilico/

Digital/ News/ News/ News/ R&D

Verge Genomics takes AI-sourced drug for ALS into clinic

Phil Taylor amyotrophic lateral sclerosis, artificial intelligence, digital, drug discovery, Verge Genomics 0 Comment

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using

Verge Genomics takes AI-sourced drug for ALS into clinic

https://pharmaphorum.com/news/verge-genomics-takes-ai-sourced-drug-for-als-into-clinic/

Simplifying the clinical trial process with automated metadata management

Digital/ News/ News/ News/ R&D

Phesi launches AI-driven trial accelerator, saving $7m per trial

Nicole Raleigh artificial intelligence, biopharma, clinical trials, cost-effectiveness, patient centricity, Phesi, trial accelerator 0 Comment

Yesterday, global provider of patient-centric data analytics, Phesi launched its AI-driven Trial Accelerator Platform, an integrated SaaS solution

Phesi launches AI-driven trial accelerator, saving $7m per trial

https://pharmaphorum.com/news/phesi-launches-ai-driven-trial-accelerator-saving-7m-per-trial/

Digital/ News/ News/ News/ R&D

GSK turns to AI specialist Tempus for R&D productivity boost

Phil Taylor artificial intelligence, clinical trials, drug discovery, GlaxoSmithKline, machine learning, partnering, Target Discovery, Tempus 0 Comment

One of the first actions by GSK’s recently appointed chief scientific officer, Tony Wood, has been to expand

GSK turns to AI specialist Tempus for R&D productivity boost

https://pharmaphorum.com/news/gsk-turns-to-ai-specialist-tempus-for-rd-productivity-boost/

Illumina_collaboration_with_AstraZeneca_image

Digital/ News/ News/ News/ R&D

AstraZeneca builds its AI capabilities again with Illumina tie-up

Phil Taylor artificial intelligence, AstraZeneca, drug discovery, Illumina, partnering, Target Discovery 0 Comment

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence

AstraZeneca builds its AI capabilities again with Illumina tie-up

https://pharmaphorum.com/news/astrazeneca-builds-its-ai-capabilities-again-with-illumina-tie-up/

Digital/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

Investment fuels AI-driven development of breakthrough genomic medicines

mike.smith@pharmaphorum.com artificial intelligence, Debiopharm, genomic medicine, genomic therapies, in silico, Omnes Capital, payload, precision medicine, vector, WhiteLab Genomics 0 Comment

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to

Investment fuels AI-driven development of breakthrough genomic medicines

https://pharmaphorum.com/digital/investment-fuels-ai-driven-development-of-breakthrough-genomic-medicines/

Digital/ News/ News/ News/ Patients

Meet Florence, WHO’s AI-powered digital health worker

Phil Taylor artificial intelligence, chatbot, digital, digital health, Soul Machines, World Health Organisation 0 Comment

An artificial intelligence-powered digital health worker has been unveiled by the World Health Organisation (WHO) as its latest

Meet Florence, WHO’s AI-powered digital health worker

https://pharmaphorum.com/news/meet-florence-whos-ai-powered-digital-health-worker/

Digital/ News/ News

Data-crunching specialist CytoReason signs $110m Pfizer alliance

Phil Taylor artificial intelligence, Biomarkers, CytoReason, digital, digital health, partnering, Pfizer 0 Comment

Three years after it started working with Pfizer, artificial intelligence-powered drug discovery specialist CytoReason has converted the relationship

Data-crunching specialist CytoReason signs $110m Pfizer alliance

https://pharmaphorum.com/news/data-crunching-specialist-cytoreason-signs-110m-pfizer-alliance/

Digital/ News/ News

Why does your address raise your risk of heart attack? AI seeks answers

Phil Taylor artificial intelligence, cardiovascular disease, demographics, digital, health, Microsoft, Novartis 0 Comment

It’s well known that where you live can have a profound impact on your risk of heart attack

Why does your address raise your risk of heart attack? AI seeks answers

https://pharmaphorum.com/news/why-does-your-address-raise-your-risk-of-heart-attack-ai-seeks-answers/

Trending

artificial intelligence

Login